Fluticasone furoate, umeclidinium and vilanterol dry powder triple therapy inhaler

Description

In this Product Explainer, Respiratory Physician Dr Kwok Yan explains the role of fluticasone furoate, umeclidinium and vilanterol dry powder triple therapy inhaler for the maintenance treatment of asthma in adult patients who are not adequately controlled with an ICS+LABA (7 mins).

This educational activity was developed by Healthed at the request of and with funding from GSK.

PM-AU-FVU-OGM-220003 approved June 2022

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Expert panel – A/Prof Samantha Hocking & Dr Terri-Lynne South, facilitated by A/Prof Ralph Audehm

Expert panel – A/Prof Samantha Hocking & Dr Terri-Lynne South, facilitated by A/Prof Ralph Audehm

GLP 1s & Sarcopenia: Fact vs Hype

Dr Deb Mills

Dr Deb Mills

The New Dengue Vaccine – What You Need to Know

Dr Robert Hungerford

Dr Robert Hungerford

Hypertriglyceridaemia – Causes, Assessment & Management of CV Risk

A/Prof Michelle Rodrigues

A/Prof Michelle Rodrigues

Management of Photoageing

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Dr Kwok Yan

expert

Dr Kwok Yan

Respiratory Physician

Date published: 14 June 2022